Original Research Article

Tennis elbow: a prospective comparative clinical study comparing the outcome of conservative management local infiltrations of leucocyte enriched platelet-rich plasma and glucocorticoid

Kamal Kumar Arora¹, Priti Chaudhary², Rajesh Kapila¹, Raminder Singh¹*

¹Department of Orthopedics, GMC Amritsar, Punjab, India
²AIIMS Bathinda, Punjab, India

Received: 04 September 2022
Revised: 04 October 2022
Accepted: 06 October 2022

*Correspondence:
Dr. Raminder Singh,
E-mail: KKA1967@rediffmail.com

ABSTRACT

Background: Lateral epicondylitis is a painful condition of the elbow, characterised by pain and tenderness with resisted wrist extension. This study was carried out to evaluate the comparative efficacy of the local infiltration of leucocyte enriched platelet rich plasma (L-PRP) and methylprednisolone in patients with lateral epicondylitis.

Methods: Sixty adult patients, between the ages 30 to 50 years, diagnosed with lateral epicondylitis of more than 12 weeks, were enrolled in the prospective randomised study. Their medical history and previous conservative treatment were recorded; the clinical evaluation of the tendinitis was made with the visual analogue scale (VAS), the disabilities of the arm, shoulder, and hand (DASH) outcome scores, the modified elbow performance index (MEPS), the functional assessment by patient-rated tennis elbow evaluation (PRTEE), together with the laboratory investigations. The patients were randomised using the computer-generated alphabets into two groups of 30: group A received PRP, and group B received corticosteroid.

Results: Patients were seen at 4, 8 and 12 weeks to evaluate the post-injection status. VAS, DASH, and PRTEE scores were significantly reduced, and MEPS was significantly improved in group A compared to group B.

Conclusions: PRP leads to superior healing with long-term therapeutic advantages compared to corticosteroids though it takes a little longer to have its effect.

Keywords: Corticosteroid, Lateral epicondylitis, Leucocyte activated platelet rich plasma, Tennis elbow

INTRODUCTION

Elbow tendinopathy occurs at least five times more often and predominantly occurs on the lateral rather than on the medial aspect of the joint, with a 4:1 to 7:1 ratio and is called as lateral epicondylitis, “[Tennis elbow” as in a study of 200 tennis players aged >30, 50% had symptoms of lateral epicondylitis at some stage], and lately proposed as lateral elbow (or epicondyle) tendinopathy (LET)]. It affects 1-3% of the population, with those 35-50 years old most commonly being affected. If a patient is <35, it is important to consider differential diagnosis (growth plate disorder, referral from the cervical spine).

If a patient is >50, osteoarthritis, referred cervical spine pain can be a possibility.

Lateral epicondylitis is equally common in both sexes. Bilateral involvement is rare, the dominant arm has the greatest chance of the occurrence of lateral epicondylitis. Twenty percent of cases persist for more than a year.

Explained first in 1873, it often is non-traumatic, with piercing pain felt at the lateral epicondyle, aggravating with grasping and rotatory movements, and wrist palmar flexion.
In the past, it was thought to be due to an inflammation of the common extensor origin of the forearm.1 \(^2\) Recently, this hypothesis has been rejected on histopathological basis, and the term 'epicondylitis' itself is declared as misnomer.2\(^4\) Now it is postulated that it is a form of tendinosis resulting from repetitive stress-mediated degeneration of the common extensor tendon origin.5\(^6\)

Researchers have now proposed a pathophysiological integrative model which hypothesises an integration of local tendon pathology, changes in the pain system and impairment in the motor system as causal factors behind the origin of tennis elbow.7

Aetiologically lateral epicondylitis may be due to (a) inflammation in ECRB, and/or (b) due to microscopic tearing with formation of reparative tissue (angio-fibroblastic hyperplasia) in the origin of the extensor carpi radialis brevis (ECRB) muscle, (c) microscopic or macroscopic tears of the common extensor origin, (d) a degenerative process with increased fibro-plasias, vascular hyperplasia, proteoglycans and glycosaminoglycans, and disorganized and immature collagen, (e) hypo vascularity, as a result of which the tendinous unit is unable to respond adequately to repetitive forces transmitted through the muscle, resulting in declining functional tolerance.

Histology there is "collagen disorientation, disorganisation, and fibre separation by increased proteoglycan content, increased cellularity, neovascularisation, with local necrosis in the involved tendon.

It is a tendinopathy involving the extensor muscles of the forearm mainly extensor carpi radialis longus (ECRL) and extensor carpi radialis brevis (ECRB) originating from the common extensor origin, though in few cases, the insertion of the extensor carpi radialis brevis is also involved. Occasionally tendinopathy may include others muscles such as extensor digitorum (ED), and extensor carpi ulnaris (ECL).

Contractile overloads are the primary cause of lateral epicondylitis. It occurs often in repetitive monotonous upper extremity doings such as computer usage, heavy lifting, powerful forearm pronation and supination against resistance, and repetitive vibration. This chronic condition also seen in other sports activities such as squash, badminton, baseball, swimming and field throwing events.

Researchers have identified three risk factors for lateral epicondylitis: (a) handling tools heavier than 1 kg, (b) handling loads heavier than 20 kg at least 10 times per day, and (c) repetitive movements for more than 2 hours per day. Other risk factors are overuse, repetitive movements, training errors, misalignments, flexibility problems, ageing, poor circulation, strength deficits or muscle imbalance and psychological factors.

In India, electricians, carpenters, gardeners, people with repetitive monotonous one-sided movements in their jobs also frequently present with this condition.

Lateral epicondylitis result in hyaline degeneration of the origin of the extensor tendon. Manual tasks requiring manipulation of the hand lead to maladaptation in ECRB tendon structure that led to pain over the lateral epicondyle.

Clinically there is maximum point tenderness at the common extensor tendon origin, 5 mm anterior, and just distal to the extensor carpi radialis brevis (ECRB) and extensor digitorum communis (EDC) muscles with lessened grip strength, inadequate supination, and dorsiflexion movement of the wrist.2

Numerous treatment options including physiotherapy, corticosteroid infiltrations, non-steroidal anti-inflammatory drugs, bracing, and acupuncture, as well as open and arthroscopic surgical debridement, have been supported for it.1\(^3\)

Leucocyte enriched activated platelet-rich plasma (L-aPRP) is a revolutionary innovative treatment possibility.8\(^-\)14 Leucocyte laden, platelet-rich plasma, activated with thrombin, instils numerous growth factors to the damaged site.15\(^-\)18 A high concentration of these growth factors repairs tendon and ligament damage, thus hastening the tendon curative course.16\(^-\)21 During this healing process, tendons are much more receptive to circulation-derived/locally produced growth factors, most of which are mass-produced within the PRP.22,23,27

In this study, the comparative efficacy of a single administration of locally infiltrated L-aPRP, glucocorticoid, each as a treatment modality for lateral epicondylitis.

**METHODS**

This was a prospective comparative study of 60 patients of either sex, having lateral epicondylitis, from May 2021 to April 2022 at a tertiary institute [Government medical college, Amritsar] of Punjab, India, to compare the efficacy of locally infiltrated leucocyte enriched, activated platelet-rich plasma (L-aPRP) to glucocorticoid, single shot infiltration, as a treatment modality for lateral epicondylitis. This study was done on the outpatient department (OPD) patients who did not respond to other conservative treatment methods for lateral epicondylitis like non-steroidal anti-inflammatory drugs (NSAIDs), physiotherapy, tennis elbow support application and/or changing the nature of their job. After obtaining verbal and written consent for their inclusion into the study, the procedure was explained. In addition, prior approval of the institutional ethical committee (IEC) was also obtained. Two groups of 30 patients each, selected by an allocation through computer-generated alphabetical, for
each method of infiltration and were named as group A and B to assess each drug infiltrated locally.

**Inclusion criteria**

Patients aged between 30-50 years, of either sex, pain due to one-sided lateral epicondylitis that persisted for at least 12 weeks, tenderness on pressure limited to regions around the elbow joint, complaints of pain during resisted extension of the middle finger or the wrist (Maudsley’s test) and positive Cozen’s test, Thomson’s test and/or Mill’s test were included in the study.

**Exclusion criteria**

Patients with blood sugar level of 180 mg% or above (even with anti-diabetic drugs), cervical radiculopathy, rheumatoid arthritis, pregnancy, haemoglobin <10 mg/dl, platelet count <150,000/mm$^3$, patients on aspirin, or similar anticoagulant drugs, fibromyalgia, pain in hand or shoulder or neck in the same upper limb, ulcers over the elbow, steroid injection within the last three months and tumours in the upper limb were excluded from the study.

Infiltration of a single dose of 3 cc freshly prepared autologous L-aPRP for group A patients, and 1 ml (40 mg) of methylprednisolone in 2 ml of (1%) 10mg/ml lignocaine for group B patients, was administered in the outpatient department (OPD).

The autologous leucocyte enriched, activated platelet-rich plasma (L-aPRP) was prepared using desktop size, a 9001-2000 ISO certified R-23 centrifuge apparatus.

Autologous L-aPRP, 1000000 platelets per microlitre of blood with leucocytes) was obtained from freshly drawn 30 cc of venous blood with 22 G needle using 50cc disposable syringe, from the patient with an added anticoagulant (sodium citrate). The collected blood, under sterile conditions, was subjected to two sets of centrifugations (spins).

The first spin, known as hard spin (more than 3000 rpm for 15 minutes), separated the red blood cells (RBC) from the plasma containing the platelets, leucocytes, and clotting factors. Three layers resulted from the hard spin: an upper layer containing platelets and leucocytes, a middle layer known as theuffy coat containing only leucocytes, and a bottom layer containing red blood cells (RBC). This bottom layer of red blood cells was separated and discarded.

The second spin, called soft spin (more than 2000 rpm for 5 minutes), separated the L-PRP in the bottom of the tube from the platelet poor plasma (PPP) at the top of the tube by the removal of more red blood cells and creating a bottom layer rich in platelets and leucocytes. The bottom layer was further activated with thrombin. This leucocyte enriched, activated platelet-rich plasma (L-aPRP) was used for infiltration in group A patients.

Plain radiographs in two views of the affected elbow were done to exclude any bony pathology. Ultrasound and magnetic resonance imaging (MRI) confirmed the presence and extent of tendon injury.

Before infiltration, pain and elbow function were assessed using four different measuring scores.

The Mayo elbow performance score (MEPS) (Table 1, Figure 1) reflected the elbow function of the patient and incorporated pain, movement, stability and activity of daily living. Out of a total score of 100 (100, the best one and 0, the worst one), the pain had 45 points, movement (range and arc of motion) 20, and stability 10, while daily functioning activities had 25 points.

### Table 1: MEPS

| Function                  | Point score |
|---------------------------|-------------|
| **Pain (45 points)**      |             |
| None                      | 45          |
| Mild                      | 30          |
| Moderate                  | 15          |
| Severe                    | 00          |
| **Motion (20 points)**    |             |
| Arc 100°                  | 20          |
| Arc 50° to 100°           | 15          |
| Arc 2°                   | 05          |
| **Stability (10 points)** |             |
| Stable                    | 10          |
| Moderate instability      | 00          |
| Gross instability         | 00          |
| **Stability (10 points)** |             |
| Stable                    | 10          |
| Moderate instability      | 00          |
| Gross instability         | 00          |
| **Daily functions (25 points)** |         |
| Combing hair              | 05          |
| Feeding oneself           | 05          |
| Hygiene                   | 05          |
| Putting on shirt          | 05          |
| Putting on shoes          | 05          |
| **Maximum possible total** | 100        |

VAS (Figure 2 and 3) measured a characteristic or attitude of pain noted by the patients. Scores ranged from 0 (no pain) to 100 (severest pain). The VAS score recorded by measurement in millimetres from the right-side end of the line up to the point that the patient marked. The outcome was measured by the changes in pain at pre-injection and subsequently at four, eight and 12 weeks.

The DASH (Table 2, Figure 4) had 30 items with self-report questionnaires structured to assess physical activity and symptoms. The scores for 30 items are taken to calculate a total score ranging from 0 (no disability) to 100 (severest disability). A minimum of 27 of the 30 items must be completed for a score to be calculated.
| Activity                                      | Difficulty                        |
|-----------------------------------------------|-----------------------------------|
| Open a tight jar/new jar                      | No difficulty Mildly difficult    |
| Write                                         | No difficulty Mildly difficult    |
| Turn a key                                     | No difficulty Mildly difficult    |
| Prepare a meal                                 | No difficulty Mildly difficult    |
| Push open a heavy door above the level of head| No difficulty Mildly difficult    |
| Place an object on a shelf                    | No difficulty Mildly difficult    |
| Do heavy household jobs                        | No difficulty Mildly difficult    |
| Garden or yard work                            | No difficulty Mildly difficult    |
| Make a bed                                     | No difficulty Mildly difficult    |
| Carry shopping bag/briefcase                  | No difficulty Mildly difficult    |
| Carry a heavy object                           | No difficulty Mildly difficult    |
| Change light bulb overhead                    | No difficulty Mildly difficult    |
| Wash/blow dry your hair                       | No difficulty Mildly difficult    |
| Wash your back                                 | No difficulty Mildly difficult    |
| Put on a pull over sweater                    | No difficulty Mildly difficult    |
| Use a knife to cut food                       | No difficulty Mildly difficult    |
| Recreational activities which require little  | No difficulty Mildly difficult    |
| effort (e.g., knitting, card playing)         | No difficulty Mildly difficult    |
| Recreational activities in which you take     | No difficulty Mildly difficult    |
| some forces or impacts through your arm,      | No difficulty Mildly difficult    |
| shoulder, or hand (e.g., hammering, tennis,   | No difficulty Mildly difficult    |
| etc.)                                         | No difficulty Mildly difficult    |
| Recreational activities in which you move     | No difficulty Mildly difficult    |
| your arm freely (e.g., playing badminton)     | No difficulty Mildly difficult    |
| Manage transposition needs                   | No difficulty Mildly difficult    |
| (getting one place to another)                | No difficulty Mildly difficult    |
| Sexual activities                              | No difficulty Mildly difficult    |
| During past week, to what extent your arm,    | Not at all Slightly Moderately    |
| shoulder/ hand problem interfered with your   | Quite a bit                      |
| normal social activities with family,         | Unable                           |
| friends, neighbors?                           |                                   |
| During past week, were you limited in your    | Not limited Slightly limited      |
| work as a result of your arm, shoulder/ hand  | moderately limited               |
| problem?                                       | Very limited                     |
| Arm, shoulder/ hand pain                      | None Mild moderate               |
| Arm, shoulder, or hand pain when you          | None Mild moderate               |
| performed any specific activity?              | None Mild moderate               |
| Tingling (pins and needles) in your arm,      | None Mild moderate               |
| shoulder/ hand                                | None Mild moderate               |
| Weakness in your arm, shoulder, or hand       | None Mild moderate               |
| Stiffness arm, shoulder hand                  | None Mild moderate               |
| Last week how much difficulty have you        | No difficulty Mildly difficult   |
| sleeping because of pain                      | Moderately difficult             |
|                                               | Severely difficult               |
|                                               | Can’t sleep                      |
Table 3: PRTEE—patient rated tennis elbow evaluation.

| Item                              | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|-----------------------------------|---|---|---|---|---|---|---|---|---|---|----|
| **Pain**                          |   |   |   |   |   |   |   |   |   |   |    |
| Pain-When it is at its worst      | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| Pain-At rest                      | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| Pain-When lifting a heavy object  | 0 | 1 | 1 | 2 | 3 | 4 | 5 | 5 | 6 | 6 | 7  |
| Pain-When doing a task with repeated elbow movement | 0 | 1 | 2 | 3 | 4 | 4 | 5 | 5 | 6 | 6 | 7  |
| How often do you have pain?       | 0 | 1 | 2 | 3 | 4 | 4 | 5 | 5 | 6 | 6 | 7  |
| **Specific activities**           |   |   |   |   |   |   |   |   |   |   |    |
| Comb my hair                      | 0 | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 3 | 4 |    |
| Eat with a fork or spoon          | 0 | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 3 | 4 |    |
| Pull a heavy object               | 0 | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 3 | 4 |    |
| Use my arm to rise from a chair   | 0 | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 4 | 4 | 5  |
| Carry a 10 lb object with my arm at my side | 0 | 1 | 2 | 2 | 3 | 3 | 4 | 4 | 4 | 5 |    |
| Throw a small object, such as a tennis ball | 0 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 4 |    |
| Use a telephone                   | 0 | 1 | 1 | 2 | 2 | 3 | 3 | 3 | 4 | 4 | 5  |
| Do up buttons on the front of my shirt | 0 | 1 | 1 | 2 | 2 | 3 | 3 | 3 | 4 | 4 | 5  |
| Wash my opposite armpit           | 0 | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 3 | 4 | 5  |
| Tie my shoe                       | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 3 |    |
| Turn the doorknob and open a door | 0 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 4 |    |
| **Usual activities**              |   |   |   |   |   |   |   |   |   |   |    |
| Personal activities (dressing, washing) | 0 | 1 | 1 | 2 | 2 | 3 | 3 | 4 | 5 | 6 | 7  |
| Household work (cleaning, maintenance) | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| Work (your job or everyday work)  | 0 | 1 | 1 | 2 | 2 | 3 | 3 | 4 | 4 | 4 | 5  |
| Recreational activities           | 0 | 1 | 1 | 2 | 2 | 3 | 3 | 3 | 4 | 4 | 5  |

PRTEE (Table 3, Figure 5) was for the functional assessment of the elbow joint. It was a 15-item questionnaire designed to measure forearm pain and disability in patients with LE. The PRTEE consisted of two subscales: pain subscale and the function subscale; best score was zero, and the worst score 100. Thus, a total score was the sum of both pain and function.33

All infiltrations were done under sterile conditions using a 22-gauge needle locally directly over the centre of the lateral epicondyle, perpendicular to the skin (if the patient had sufficient subcutaneous fat) or at a 45° angle to a depth of 0.75 to 1.5 cm. The patient was kept in a supine position for 15 minutes after the infiltration and then sent home with instructions to restrict the use of the arm and elbow for the next 24 hours.

Post infiltration scores were re-evaluated, using the same questionnaires used pre-infiltration to evaluate the efficacy of one treatment modality over the other in the management of lateral epicondylosis.

The IBM SPSS software package version 20.0 (Armonk, NY: IBM Corp) was used for data analysis. Number and percent were used to describe qualitative data. Variables normality of distribution was verified using the Kolmogorov-Smirnov, Shapiro and D’Agostino tests. Range (minimum and maximum), mean, standard deviation used to describe quantitative data. Significance of the results was judged at the 5% level. P value was statistically significant at p≤0.05.

RESULTS

In this study, the middle aged (30-50 years) group was commonly involved, especially as the skilled manual workers without any significant gender bias.

Most of the patients opted for the local infiltrations, as there was no improvement in their signs/symptoms with other conservative methods.

Post infiltration, the patients were followed up in the orthopaedics outpatient department at the 3rd week, 6th week, as well as the 12th weeks for assessment of the clinical improvement in signs or the symptoms of the lateral epicondylitis.

Functionality parameters from their pre-infiltration status at the elbow joint with infiltration of L-aPRP infiltrations had a continuous progressive, positive effect on the healing process, with a significant decrease of VAS, DASH, PRTEE scores and the significant rise MEPS score.

Gluco-corticoid infiltrations decreased the severity of pain and increased MEPS, DASH, and PRTEE functionality due to anti-inflammatory action (Figure 1-4), yet those effects were short-lived and stopped improving further after a few weeks. In addition, a few (n=4) patients reported the hypo-pigmentation at the infiltration site.
Glucocorticoid and L-aPRP proved to be almost equally effective at the short-term follow-up (4 and 8 weeks) with slightly better performance by glucocorticoid, while PRP had an upper hand to glucocorticoid in the long term (at 12 weeks) follow-up of the patients (Table 4 and 5). Post infiltration increase in the intensity of pain was present in 15 patients, 5 in steroid and 10 in L-aPRP group, which was managed by oral analgesics [(piroxicam 20 mg or (etoricoxib 90mg + thiocolchicoside 8 mg)] for 3 days.

None of the patients had any sign of infection after the procedure and the results of observations of individual patients were pooled for each intervention group.

Data analysis was performed using SPSS version 20 [SPSS Inc, Chicago, Illinois, USA]. Numerical data were expressed as mean, ± standard deviation (SD) or per cent as proportionate to the sample size. The significance of the difference between the two groups was determined
using the "p" value. A "p" value less than 0.05 was considered significant.

Table 4: Comparative evaluation of different functional scores with different modalities (pre and post infiltration).

| Scores                  | Platelet rich plasma group | Glucocorticoid group |
|-------------------------|---------------------------|----------------------|
| **Comparison of VAS score** |                           |                      |
| Pre-treatment           | 70.4                      | 70.8                 |
| At 4 weeks              | 50.5                      | 50.9                 |
| At 8 weeks              | 40.1                      | 50.4                 |
| At 12 weeks             | 30.5                      | 40.5                 |
| **Comparison of DASH score** |                         |                      |
| Pre-treatment           | 56.2                      | 55.2                 |
| At 4 weeks              | 56.2                      | 42.0                 |
| At 8 weeks              | 43.8                      | 35.8                 |
| At 12 weeks             | 29.1                      | 32.0                 |
| **Comparison of PRTEE score** |                      |                      |
| Pre-treatment           | 68.6                      | 67.8                 |
| At 4 weeks              | 56.2                      | 62.2                 |
| At 8 weeks              | 43.8                      | 54.8                 |
| At 12 weeks             | 32.6                      | 46.6                 |
| **Comparison of MEPS score** |                    |                      |
| Pre-treatment           | 62.2                      | 63.9                 |
| At 4 weeks              | 88.6                      | 78.8                 |
| At 8 weeks              | 93.2                      | 88.1                 |
| At 12 weeks             | 98.1                      | 88.4                 |

Table 5: Comparative outcome of management with infiltrations of La-PRP, glucocorticoid and normal saline.

| Demographic/clinical characteristics | Activated PRP group | Glucocorticoid group | P value |
|--------------------------------------|---------------------|----------------------|---------|
| **Gender**                           |                     |                      |         |
| Male                                 | 11                  | 09                   |         |
| Female                               | 09                  | 11                   |         |
| **Mean age (Years)**                 | 34.6                | 33.8                 |         |
| **Side involved**                    |                     |                      |         |
| Right side                           | 11                  | 09                   |         |
| Left side                            | 09                  | 11                   |         |
| **Diabetes mellitus**                | (Controlled) 01     | 00                   |         |
| **Comparisons of MEPS (average) (At 12 weeks)** |                  |                      | <0.05   |
| Pre-infiltration                     | 62.2                | 63.9                 |         |
| At 4 weeks                           | 88.6                | 78.8                 |         |
| At 8 weeks                           | 93.2                | 88.1                 |         |
| At 12 weeks                          | 98.1                | 88.4                 |         |
| **Visual analogue score (At 12 weeks)** |                      |                      | <0.05   |
| Pre-infiltration                     | 70.4                | 70.8                 |         |
| At 4 weeks                           | 50.5                | 50.9                 |         |
| At 8 weeks                           | 40.1                | 50.4                 |         |
| At 12 weeks                          | 30.5                | 40.5                 |         |
| **DASH score (At 12 weeks)**         |                     |                      | <0.05   |
| Pre-infiltration                     | 56.2                | 58.2                 |         |
| At 4 weeks                           | 56.2                | 42.0                 |         |
| At 8 weeks                           | 43.8                | 35.8                 |         |
| At 12 weeks                          | 29.1                | 32.0                 |         |
| **PRTEE score (At 12 weeks)**        |                     |                      | <0.05   |
| Pre-infiltration                     | 62.2                | Pre-infiltration     |         |
| At 4 weeks                           | 56.2                | 62.2                 |         |
| At 8 weeks                           | 43.8                | 54.8                 |         |
| At 12 weeks                          | 32.6                | 46.6                 |         |
DISCUSSION

Lateral epicondyritis, with an incidence of 1% to 3%, is a familiar chronic disabling painful degenerative condition, occurring at the common origin of the wrist and finger extensors at the elbow due to overuse, and abnormal microvascular responses during post-injury reparative process. The basic pathology is in the origin of the extensor carpi radialis brevis (ECRB) tendon, but sometimes the anteromedial edge of the extensor digitorum communis (EDC) and the deep surface of the extensor carpi radialis longus (ECRL) may also be involved. In addition, there is hypervascularity and erratic neovascularisation of the tendon, once injured, leading to erratic revascularisation, defective fibrosis and adhesion, and partial loss of normal function. This aberration from normalcy in structure/rearrangement often makes the tissue vulnerable to re-injury.

The injured tendon also develops post-injury interstitial gaps (microtears), discontinuous collagen fibres, degenerative changes like lipid deposition, proteoglycan accumulation, and calcification. It also has a lesser total collagen content, a greater collagen type III/collagen type I ratio, elevated expression of matrix metalloproteinases (MMPs), MM-1, MMP-3, and MMP-9, and decreased expression of the MMP inhibitors. Apart from deviations in tendon metabolism, there is intense inflammation at the micro injury site, impairing healing of the tendon tissue if left untreated.

Despite the proliferation of different treatment options for the lateral epicondyritis, reluctance on the part of the patients sways them towards the infiltration therapy either with glucocorticoid or L-aPRP.

Corticosteroid injection was the gold standard treatment earlier due to the rapid improvement in signs and symptoms after treatment. However, after a few weeks, there is a recurrence of pain, probably due to the permanent damage of the tendon and hypo pigmentation at the infiltration site. Moreover, optimal timing, dosage, injection technique, and injection volume remain unanswered to date.

Autologous PRP was first used to avoid the excessive transfusion of homologous blood products, following open heart surgery. It is an ideal biological autologous blood derived component as it is readily available, cost-effective, preventing infection at the infiltration site as it is leucocyte enriched, is without any immune reaction and has potent growth factors required for tendon healing. Leucocyte enriched activated platelets (L-aPRP), when infiltrated, release high concentrations of transforming growth factors, beta (TGF-β), platelet-derived growth factors (PDGF), fibroblast growth factors (FGF), vascular endothelial growth factors (VEGF) and cytokines, through the alfa granules contained within, at the injected site. These growth factors play significant roles in cell proliferation, chemotaxis, cell differentiation, and angiogenesis. In addition, the platelets also secrete several cell adhesion molecules, including fibronectin, fibrin and vitronectin, promoting cell migration and the biological activity of L-aPRP; and promote healing by acting as conductive matrix or scaffold upon which cells can adhere and initiate the healing process. Decrease in intensity of pain, increase in functional activities, and elbow stability were the main outcome parameters in this study to improve signs and symptoms of lateral epicondyritis.

In a study in 2003 to manage lateral epicondyritis, whole blood was injected into patients with a success rate of 79%, but multiple injections were necessary for 32% of patients.

Another study in 2006 reported a success rate of 93% with platelet-rich plasma and a 65% success rate with corticosteroids.

PRP was injected in the elbow of 31 patients in a study in 2011 with failed previous conservative treatment and met the criteria of successful treatment in 90% of patients with a 25% reduction in the worst pain score for at least one follow-up visit, with no further intervention at 12-month interval.

A comparative study in 2011 compared the effectiveness of autologous platelet-rich plasma with steroid therapy in lateral epicondyritis and concluded that platelet-rich plasma injection was safe and easy. Concerning functional impairment, the corticosteroid group showed better results during the initial period and then returned to the baseline. Whereas in the platelet-rich plasma group, symptoms improved progressively and consistently. There was a significant difference in pain and functional impairment after platelet-rich plasma application even after one year. In his study, in the platelet-rich plasma group, the pre-injection DASH score of 54.3 declined to 43.1 at four, 31.2 at 12 weeks. The pre-injection VAS score of 69.0 declined to 55.7 at four weeks, 45.1 at eight and 40.2 at 12 weeks. DASH score among the steroid group declined similarly up to 12 weeks with a decline of VAS score from the pre-injection score of 66.2 to 44.3 at four and 38.5 at 12 weeks.

In the present study, the DASH score among the platelet-rich plasma group declined from a pre-injection score of 56.2, which was the same at four weeks, decreased to 43.8 at eight and 29.1 at 12 weeks. Similarly, the VAS score among the platelet-rich plasma group declined from the pre-injection score of 70.4 to 50.5 at four, 40.1 at eight and 30.5 at 12 weeks.

In the present study, the DASH score among the steroid group started to decline from the pre-injection score of 55.2 to 42.0 at four, 35.8 at eight and 34.0 at 12 weeks. In this study, the VAS score among the steroid group declined from 70.8 of pre-injection score to 50.9 at four, 50.4 at eight and 40.5 at 12 weeks.
In another randomised study in 2015, 30 lateral epicondylitis patients, aged 18-60 years, with chronic pain (>6 months) were randomised into two groups: group I received a PRP injection and group II received a corticosteroid injection. Patients were assessed using the VAS for pain and DASH score. In addition, an ultrasound evaluation of the common extensor origin was performed. At six months, the number of patients positive for various ultrasonographic findings generally decreased. PRP appeared to enable biological healing of the lesion, whereas corticosteroids appeared to provide short-term, symptomatic relief but resulted in tendon degeneration. Improvement in tendon morphology was greater after PRP injection than after corticosteroid injection.45

Another randomised-controlled study done in 2013 included 60 patients with lateral epicondylitis divided into three groups. The local injection treatments included a corticosteroid injection of 1ml triamcinolone 40 mg/ml+2 ml lidocaine 10 mg/ml, a saline injection of 3 ml, and 3 ml to 3.5 ml PRP. All patients were assessed at one and at three months by ultrasonography and PRTEE score. The study found that in terms of PRTEE at one month, corticosteroid was superior to both PRP and saline, but at three months, its effect declined.46

A study in 2015 carried out on 65 patients with lateral epicondylitis, divided them randomly into two groups: group A received a single infiltration of one ml PRP with an absolute platelet count of at least one million platelets/mm³, and group B had a single injection of one ml (40 mg) methylprednisolone. VAS was used to assess post infiltration pain. It had greater improvement with a corticosteroid injection after 15 days and one month than with PRP; however, it declined, and at the end of three months.47

In a study in 2017, improvement in pain was highly significant in the PRP group compared to the corticosteroid group (PRP injection, and group III received a corticosteroid injection. Patients were reassessed clinically and by ultrasound after three months. They showed that VAS and PRTEE scores were significantly reduced after injection in group II compared to group I and III. Moreover, the reductions in VAS and PRTEE were significantly different in group III in comparison with group I.48 With the results of the 12 weeks follow-up, the outcome in the platelet-rich plasma group was maintained, whereas outcome in corticosteroid group declined; and significantly, the platelet-rich plasma group which had poorer pre-injection VAS scores but better scores after 12 weeks. This strengthens the view that the platelet-rich plasma is undoubtedly a better alternative to corticosteroid in lateral epicondylitis.

**Limitation**

However, the limitation of present study is the very small sample size, and a larger database will be needed to confirm its findings.

**CONCLUSION**

L-aPRP is more beneficial therapeutically than corticosteroid infiltration as it is cost-effective and readily available. It contains growth factors for healing, and being an autologous preparation, it is immunologically compatible and has antibacterial activity from enrichment with the leucocytes. Moreover, it has a continuous, longer duration of action. It enables better healing as it leads to a more homogenous tendon arrangement and systematic neovascular proliferation post-injury in occupational and sports injuries.

**Funding: No funding sources**

**Conflict of interest: None declared**

**Ethical approval: The study was approved by the Institutional Ethics Committee**

**REFERENCES**

1. Murray DJ, Javed S, Jain N, Kemp S, Watts AC. Platelet-Rich-Plasma Injections in Treating Lateral Epicondylitis: A Review of the Recent Evidence. J Hand Microsurg. 2015;7(2): 320-5.

2. McMurtrie A, Watts AC. Tennis elbow and golfer’s elbow: a review article. Orthop Trauma. 2012;26(5):297-366.

3. Szabo SJ, Savoie FH 3rd, Field LD, Ramsey JR, Hosemann CD. Tendinosis of the extensor carpi radialis brevis: an evaluation of three methods of operative treatment. J Shoulder Elbow Surg. 2006;15(6):721-7.

4. Edwards SG, Calandruccio JH. Autologous blood injections for refractory lateral epicondylitis. J Hand Surg Am. 2003;28(2): 272-8.

5. Mishra A, Pavelko T. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. Am J Sports Med. 2006;34(11):1774-8.

6. Sun Y, Feng Y, Zhang CQ, Chen SB, Cheng XG. The regenerative effect of platelet-rich plasma on healing in large osteochondral defects. Int Orthop. 2010;34(4):589-97.

7. Coombes BK, Bisset L, Vicenzino B. A new integrative model of lateral epicondylalgia. Br J Sports Med. 2009;43(4):252-8.

8. Finnoff JT, Fowler SP, Lai JK, Santrach PJ, Willis EA, Sayeed YA et al. Treatment of chronic tendinopathy with ultrasound guided needle tenotomy and platelet-rich plasma injection. PM R. 2011;3(10):900-11.

9. Brown J, Sivan M. Ultrasound-guided platelet-rich plasma injection for chronic patellar tendinopathy: a case report. PM R. 2010;2(10):969-72.

10. Kon E, Filardo G, Delcogliano M, Presti ML, Russo A, Bondi A et al. Platelet-rich plasma: new clinical application: a pilot study for treatment of jumper's knee. Injury. 2009;40(6):598-603.

11. Owens RF Jr, Ginnetti J, Conti SF, Latona C. Clinical and magnetic resonance imaging outcomes following platelet rich plasma injection for chronic...
mid substance Achilles tendinopathy. Foot Ankle Int. 2011;32(11):1032-9.
12. Gossens T, Peerbooms JC, van Laar W, den Oudsten BL. Ongoing positive effect of platelet-rich plasma versus corticosteroid injection in lateral epicondylitis: a double-blind randomized controlled trial with 2-year follow-up. Am J Sports Med. 2011;39(6):1200-8.
13. Scollon-Grieve KL, Malanga GA. Platelet-rich plasma injection for partial patellar tendon tear in a high school athlete: a case presentation. PM R. 2011;3(4):391-5.
14. Hechtman KS, Uribe JW, Botto-van Demden A, Kiebzak GM. Platelet-rich plasma injection reduces pain in patients with calcific tendinitis. Orthopedics. 2011;34(2):92.
15. Yuan T, Guo SC, Han P, Zhang CQ, Zeng BF. Applications of leukocyte- and platelet-rich plasma (L-PRP) in trauma surgery. Curr Pharm Biotechnol. 2012;13(7):1173-84.
16. Zhang J, Wang JH. Platelet-rich plasma releasate promotes differentiation of tendon stem cells into active tenocytes. Am J Sports Med. 2010;38(12):2477-86.
17. Alsousou J, Ali A, Willett K, Harrison P. The role of platelet-rich plasma in tissue regeneration. Platelets. 2013;24(3):173-82.
18. Anitua E, Andía I, Sanchez M, Azofra J, del Mar Zaldueño M, De la Fuente M et al. Autologous preparations rich in growth factors promote proliferation and induce VEGF and HGF production by human tendon cells in culture. J Orthop Res. 2005;23(2):281-6.
19. Chen L, Dong SW, Tao X, Liu JP, Tang KL, Xu JZ. Autologous platelet-rich clot releasate stimulates proliferation and inhibits differentiation of adult rat tendon stem cells towards non-tenocyte lineages. J Int Med Res. 2012;40(4):1399-409.
20. Taylor DW, Peterea M, Hendry M, Theodoropoulos JS. A systematic review of the use of platelet-rich plasma in sports medicine as a new treatment for tendon and ligament injuries. Clin J Sport Med. 2011;21(4):344-52.
21. Parafioriti A, Armiraglio E, Del Bianco S, Tibalt E, Oliva F, Berardi AC. Single injection of platelet-rich plasma in a rat Achilles tendon tear model. Muscles Ligaments Tendons J. 2011;1(2):41-7.
22. Khan U, Oscleston NL, Khaw PT, McGrouther DA. Differences in proliferative rate and collagen lattice contraction between endotenon and synovial fibroblasts. J Hand Surg Am. 1998;23(2):266-73.
23. Yoshikawa Y, Abrahamsson SO. Dose-related cellular effects of platelet-derived growth factor-BB differ in various types of rabbit tendons in vitro. Acta Orthop Scand. 2001;72(3):287-92.
24. Rickert M, Jung M, Adiyaman M, Richter W, Simank HG. A growth and differentiation factor-5 (GDF-5)-coated suture stimulates tendon healing in an Achilles tendon model in rats. Growth Factors. 2001;19(2):115-26.
25. Mollov T, Wang Y, Murrell G. The roles of growth factors in tendon and ligament healing. Sports Med. 2003;33(5):381-94.
26. Kurtz CA, Loebig TG, Anderson DD, DeMeo PJ, Campbell PG. Insulin-like growth factor I accelerates functional recovery from Achilles tendon injury in a rat model. Am J Sports Med. 1999;27(3):363-9.
27. Chang J, Thunder R, Most D, Longaker MT, Lineaweaver WC. Studies in flexor tendon wound healing: neutralizing antibody to TGF-beta1 increases postoperative range of motion. Plast Reconstr Surg. 2000;105(1):148-55.
28. Dhurat R, Sukesh M. Principles and Methods of Preparation of Platelet-Rich Plasma: A Review and Author’s Perspective. J Cutan Aesthet Surg. 2014;7(4):189-97.
29. Boswell SG, Cole BJ, Sundman EA, Karas V, Fortier LA. Platelet-rich plasma: a milieu of bioactive factors. Arthroscopy. 2012;28(3):429-39.
30. Mayo Elbow Performance Score. J Ortho Trauma. 2006;20(8):S127.
31. Gould D. Visual Analogue Scale (VAS). Blackwell Science Ltd, J Clin Nurs. 2001;10:697-706.
32. Hudak PL, Amadio PC, Bombardier C. Development of an upper extremity outcome measure: the DASH (disabilities of the arm, shoulder and hand) [corrected]. The Upper Extremity Collaborative Group (UECG). Am J Ind Med. 1996; 29(6): 602-8.
33. Macdermid J. Update: The Patient-rated Forearm Evaluation Questionnaire is now the Patient-rated Tennis Elbow Evaluation. J Hand Ther. 2005;18(4):407-10.
34. Nirschl RP. Elbow tendinosis/tennis elbow. Clin Sports Med. 1992;11(4):851-70.
35. Evans RB. Managing the injured tendon: current concepts. J Hand Ther. 2012;25(2):173-89.
36. James R, Kesturu G, Balian G, Chhabra AB. Tendon: biology, biomechanics, repair, growth factors, and evolving treatment options. J Hand Surg Am. 2008;33(1):102-12.
37. Wang JH, Guo Q, LiB. Tendon biomechanics and mechanobiology—a mini review of basic concepts and recent advancements. J Hand Ther. 2012;25(2):133-40.
38. Assendelft WJ, Hay EM, Adshead R, Bouter LM. Corticosteroid injections for lateral epicondylitis: a systematic overview. Br J Gen Pract. 1996;46(405):209-16.
39. Riley GP, Curry V, De Groot J, Van EIB, Verzijl N, Hazleman BL et al. Matrix metalloproteinase activities and their relationship with collagen remodelling in tendon pathology. Matrix Biol. 2002;21(2):185-95.
40. Smidt N, Van der Windt DA, Assendelft WJ, Devillle WL, Korthals-de Bos IB, Bouter LM. Corticosteroid injections, physiotherapy, or a wait-and-see policy for lateral epicondylitis: a randomised controlled trial. Lancet. 2002;359(9307):657-62.
41. Wong SM, Hui AC, Tong PY, Poon DW, Yu E, Wong LK. Treatment of lateral epicondylitis with
botulinum toxin: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2005;143(11):793-7.

42. Sampson S, Gerhardt M, Mandelbaum B. Platelet rich plasma injection grafts for musculoskeletal injuries: a review. Curr Rev Musculoskelet Med. 2008;1(3-4):165-74.

43. Smidt N, Assendelft WJ, Arola H, Malmivaara A, Greens S, Buchbinder R et al. Effectiveness of physiotherapy for lateral epicondylitis: a systematic review. Ann Med. 2003;35(1):51-62.

44. Ferrari M, Zia S, Valbonesi M, Henriquet F, Venere G, Spagnolo S et al. A new technique for haemodilution, preparation of auto logous platelet-rich plasma and intraoperative blood salvage in cardiac surgery. Int J Artif Organs.1987;10(1):47-50.

45. GautamVK, VermaS, BatraS, BhatnagarN, Arora S. Platelet-rich plasma versus corticosteroid injection for recalcitrant lateral epicondylitis: clinical and ultrasonographic evaluation. J Orthop Surg (Hong Kong). 2015;23(1):1-5.

46. Krogh TP, Fredberg U, Stengaard-Pedersen K, Christensen R, Jensen P, Ellingsen T. Treatment of lateral epicondylitis with platelet-rich plasma, glucocorticoid, or saline: a randomized, double-blind, placebo-controlled trial. Am J Sports Med. 2013;41(3):625-35.

47. Yadav R, Kothari SY, Borah D. Comparison of Local Injection of Platelet Rich Plasma and Corticosteroids in the treatment of Lateral Epicondylitis of Humerus. J Clin Diagn Res. 2015;9(7):RC05-7.

48. Nasser MET, El Yasaki AZ, Elz El Mallah RM, Abdel azeem ASM. Treatment of lateral epicondylitis with platelet-rich plasma, glucocorticoid, or saline. A comparative study. Egypt Rheumatol Rehabil. 2017;44:1-10.

Cite this article as: Arora KK, Chaudhary P, Kapila R, Singh R. Tennis elbow: a prospective comparative clinical study comparing the outcome of conservative management local infiltrations of leucocyte enriched platelet-rich plasma and glucocorticoid. Int Surg J 2022;9:1788-98.